Oncology

Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.

According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.

When pembrolizumab is combined with immunotherapies, the incidence of grade 3 to 5 toxicities increases, especially with anti–CTLA-4 combinations.

“We’ve seen with the initial anti-CTLA-4 ipilimumab experience that, as time went by, we were better at identifying and managing toxicities,” stated Omid Hamad, MD.

Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.

DOGE hopes to solve rampant inefficiencies in US healthcare that contribute to unsustainable costs and a broken system by cutting spending and administrative waste.

Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.

Understanding patient preferences for intensive end-of-life treatment may better inform research assessing patients with terminal cancer diagnoses.

A pooled analysis found pembrolizumab has a discontinuation rate of 12.7%, and a major key to handling it is maintaining good communication between the doctor and the patient.

AI-powered tools may help alleviate doctor burnout and give clinicians more time to directly engage with patients.

Scarlett Lin Gomez, MPH, PhD, highlights facts from her research that are impacting cancer disparities and how she is finding ways to improve them.

Artificial intelligence may act as a force multiplier, with the automation of menial tasks enabling more time for clinicians to engage with patients.

Vimseltinib elicited an ORR of 40% vs 0% of matching placebo in patients with tenosynovial giant cell tumor in the phase 3 MOTION trial.

Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.

Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.

The decision impacts the phase 1 STARLING trial and additional phase 1 trials sponsored by the Moffitt Cancer Center evaluating TIDAL-01 in solid tumors.

Options like acupuncture or cannabis use may be viable to help manage symptoms related to gastrointestinal cancer treatment.

Coral Omene, MD, PhD, and Mariam Eskander, MD, MPH, discuss how to continue engagement in clinical trial enrollment for underserved populations.

TRAQinform IQ provides spatial and temporal information for each lesion from serial PET/CT scans, helping to inform the next steps for cancer treatment.

Data from the phase 2 LITESPARK-015 trial support the sNDA for belzutifan in patients with pheochromocytoma or paraganglioma.

2mg, 3mg, and 5mg extended-release capsules of everolimus have been approved for patients with TSC-associated SEGA by the FDA.

Of note, lung cancer incidence was higher among women younger than 65 compared with their male counterparts in 2021.

In considering patients’ busy lives, AI may help reduce the number of visits required to fully stage and grade cancers.

Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.

Micheal P. Bogenschutz, MD, discussed addressing unmet needs, implementation, and adverse effects related to psilocybin-assisted psychotherapy in cancer.

The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.

A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.

The RISE R-5780-01 trial will evaluate the safety and tolerability of R-5780 in patients with melanoma, basal cell carcinoma, or squamous cell carcinoma.

Patients in the ponsegromab group had significantly greater weight gain and physical activity than those in the placebo arm in a phase 2 trial.

Nearly half of patients with an ICD had a device programming encounter near the end of life, which could present an opportunity to discuss goals of care.